142 related articles for article (PubMed ID: 31319058)
21. Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study.
Brugger W; Hirsch J; Grünebach F; Repp R; Brossart P; Vogel W; Kopp HG; Manz MG; Bitzer M; Schlimok G; Kaufmann M; Ganser A; Fehnle K; Gramatzki M; Kanz L
Ann Oncol; 2004 Nov; 15(11):1691-8. PubMed ID: 15520073
[TBL] [Abstract][Full Text] [Related]
22. Effect of prior rituximab on high-dose therapy and autologous stem cell transplantation in follicular lymphoma.
Kang TY; Rybicki LA; Bolwell BJ; Thakkar SG; Brown S; Dean R; Sekeres MA; Advani A; Sobecks R; Kalaycio M; Pohlman B; Sweetenham JW
Bone Marrow Transplant; 2007 Nov; 40(10):973-8. PubMed ID: 17873917
[TBL] [Abstract][Full Text] [Related]
23. Long-term clinical and molecular remissions in patients with follicular lymphoma following high-dose therapy and autologous stem cell transplantation.
Metzner B; Pott C; Müller TH; Gebauer W; Casper J; Kraemer D; Rosien B; Schumann-Binarsch S; Thole R; Köhne CH
Ann Oncol; 2013 Jun; 24(6):1609-15. PubMed ID: 23393125
[TBL] [Abstract][Full Text] [Related]
24. A retrospective analysis of outcomes for primary mediastinal large B-cell lymphoma treated with RCHOP followed by radiotherapy or front-line autologous stem cell transplantation.
Liu X; Deng T; Guo X; Guo Y; Wang L; Zhang J; Xia Z; Zhang Q; Xue K; Cao J; Shi J; Hong X
Hematology; 2017 Jun; 22(5):258-264. PubMed ID: 27884092
[TBL] [Abstract][Full Text] [Related]
25. Autologous stem cell transplant and combination immunotherapy of rituximab and interferon-α induces prolonged clinical and molecular remissions in patients with follicular lymphoma.
Smyth L; Buckstein R; Pennell N; Weerasinghe R; Cheung MC; Imrie K; Spaner D; Piliotis E; Chodirker L; Reis M; Ghorab Z; Zhang L; Boudreau V; Miliken A; Berinstein N
Br J Haematol; 2019 Feb; 184(3):469-472. PubMed ID: 29380359
[No Abstract] [Full Text] [Related]
26. Long-term follow-up demonstrates curative potential of autologous stem cell transplantation for relapsed follicular lymphoma.
Puckrin R; Chua N; Chin K; Peters A; Duggan P; Shafey M; Storek J; Jamani K; Owen C; Stewart D
Br J Haematol; 2023 Apr; 201(2):319-325. PubMed ID: 36625160
[TBL] [Abstract][Full Text] [Related]
27. A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma.
Sabloff M; Atkins HL; Bence-Bruckler I; Bredeson C; Fergusson D; Genest P; Hopkins H; Hutton B; Mcdiarmid S; Huebsch LB
Biol Blood Marrow Transplant; 2007 Aug; 13(8):956-64. PubMed ID: 17640600
[TBL] [Abstract][Full Text] [Related]
28. Autologous transplant for relapsed follicular lymphoma: impact of pre-transplant rituximab sensitivity.
Phipps C; Gopal AK; Storer BE; Cassaday RD; Press OW; Till BG; Pagel JM; Palanca-Wessels MC; Philip M; Bensinger WI; Holmberg LA; Shustov AR; Green DJ; Chauncey T; Maloney DG; Libby EN
Leuk Lymphoma; 2015 Jan; 56(1):92-6. PubMed ID: 24707941
[TBL] [Abstract][Full Text] [Related]
29. Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era.
Nagle SJ; Woo K; Schuster SJ; Nasta SD; Stadtmauer E; Mick R; Svoboda J
Am J Hematol; 2013 Oct; 88(10):890-4. PubMed ID: 23813874
[TBL] [Abstract][Full Text] [Related]
30. Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation.
Pettengell R; Schmitz N; Gisselbrecht C; Smith G; Patton WN; Metzner B; Caballero D; Tilly H; Walewski JA; Bence-Bruckler I; To B; Geisler CH; Schots R; Kimby E; Taverna CJ; Kozák T; Dreger P; Uddin R; Ruiz de Elvira C; Goldstone AH
J Clin Oncol; 2013 May; 31(13):1624-30. PubMed ID: 23547078
[TBL] [Abstract][Full Text] [Related]
31. Zevalin and BEAM (Z-BEAM) versus rituximab and BEAM (R-BEAM) conditioning chemotherapy prior to autologous stem cell transplantation in patients with mantle cell lymphoma.
Berger MD; Branger G; Klaeser B; Taleghani BM; Novak U; Banz Y; Mueller BU; Pabst T
Hematol Oncol; 2016 Sep; 34(3):133-9. PubMed ID: 25689832
[TBL] [Abstract][Full Text] [Related]
32. High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry.
Mounier N; Canals C; Gisselbrecht C; Cornelissen J; Foa R; Conde E; Maertens J; Attal M; Rambaldi A; Crawley C; Luan JJ; Brune M; Wittnebel S; Cook G; van Imhoff GW; Pfreundschuh M; Sureda A;
Biol Blood Marrow Transplant; 2012 May; 18(5):788-93. PubMed ID: 22005647
[TBL] [Abstract][Full Text] [Related]
33. Autologous stem cell transplantation in follicular non-Hodgkin's lymphoma.
Pettengell R
Bone Marrow Transplant; 2002 Feb; 29 Suppl 1():S1-4. PubMed ID: 11840153
[TBL] [Abstract][Full Text] [Related]
34. Autologous stem cell transplantation in follicular lymphoma: a systematic review and meta-analysis.
Al Khabori M; de Almeida JR; Guyatt GH; Kuruvilla J; Crump M
J Natl Cancer Inst; 2012 Jan; 104(1):18-28. PubMed ID: 22190633
[TBL] [Abstract][Full Text] [Related]
35. Outcome determinants for transformed indolent lymphomas treated with or without autologous stem-cell transplantation.
Madsen C; Pedersen MB; Vase MØ; Bendix K; Møller MB; Johansen P; Jensen BA; Jensen P; Munksgaard L; Brown PD; Segel EK; d'Amore FA
Ann Oncol; 2015 Feb; 26(2):393-9. PubMed ID: 25411416
[TBL] [Abstract][Full Text] [Related]
36. Clearing minimal residual disease with rituximab consolidation therapy.
Brugger W
Semin Oncol; 2004 Feb; 31(1 Suppl 2):33-7. PubMed ID: 15042533
[TBL] [Abstract][Full Text] [Related]
37. Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphoma.
Andreadis C; Schuster SJ; Chong EA; Svoboda J; Luger SM; Porter DL; Tsai DE; Nasta SD; Elstrom RL; Goldstein SC; Downs LH; Mangan PA; Cunningham KA; Hummel KA; Gimotty PA; Siegel DL; Glatstein E; Stadtmauer EA
Bone Marrow Transplant; 2005 Dec; 36(11):955-61. PubMed ID: 16205727
[TBL] [Abstract][Full Text] [Related]
38. Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autólogo de Médula Osea Spanish Cooperative Group.
Sureda A; Arranz R; Iriondo A; Carreras E; Lahuerta JJ; García-Conde J; Jarque I; Caballero MD; Ferrà C; López A; García-Laraña J; Cabrera R; Carrera D; Ruiz-Romero MD; León A; Rifón J; Díaz-Mediavilla J; Mataix R; Morey M; Moraleda JM; Altés A; López-Guillermo A; de la Serna J; Fernández-Rañada JM; Sierra J; Conde E;
J Clin Oncol; 2001 Mar; 19(5):1395-404. PubMed ID: 11230484
[TBL] [Abstract][Full Text] [Related]
39. High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission.
DeFilipp Z; Li S; El-Jawahri A; Armand P; Nayak L; Wang N; Batchelor TT; Chen YB
Cancer; 2017 Aug; 123(16):3073-3079. PubMed ID: 28369839
[TBL] [Abstract][Full Text] [Related]
40. The influence of rituximab, high-dose therapy followed by autologous stem cell transplantation, and age in patients with primary CNS lymphoma.
Madle M; Krämer I; Lehners N; Schwarzbich M; Wuchter P; Herfarth K; Egerer G; Ho AD; Witzens-Harig M
Ann Hematol; 2015 Nov; 94(11):1853-7. PubMed ID: 26268792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
